• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Cerus Corporation

    4/26/24 12:00:20 PM ET
    $CERS
    EDP Services
    Technology
    Get the next $CERS alert in real time by email
    DEFA14A 1 cers-defa14a-2024_new.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a-12

    CERUS CORPORATION

    (Name of Registrant as Specified In Its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement if Other Than The Registrant)

    Payment of Filing Fee (Check the appropriate box)

     

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


     

     

     


    CoVote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Recommends Voting Items 1. The election of the three nominees for director named in the Proxy Statement, to hold office until the 2027 Annual Meeting of Stockholders. For Nominees: 01) Daniel N. Swisher Jr. 02) Frank Witney, Ph.D 03) Eric Bjerkholt 2. The approval of an amendment and restatement of the Company’s Amended and Restated 2008 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 5 million shares and to make certain other changes thereto as described further in the accompanying Proxy Statement. For 3. The approval of an amendment and restatement of the Company’s Amended and Restated Employee Stock Purchase Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 2 million shares. For 4. The approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. For 5. The ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. For NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V46689-P09249

     

     

    img111553942_0.jpgYour Vote Counts! CERUS CORPORATION 2024 Annual Meeting Vote by June 4, 2024 11:59 PM ET CERUS CORPORATION ATTN: LORI L. ROLL 1220 CONCORD AVE., SUITE 600 CONCORD, CA 94520 V46688-P09249 You invested in CERUS CORPORATION and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 5, 2024. Get informed before you vote View the Notice and Proxy Statement and our Annual Report, which includes the Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 5, 2024 8:00 a.m., Pacific Time Virtually at: www.virtualshareholdermeeting.com/CERS2024 *Please check the meeting materials for any special requirements for meeting attendance.

     

     

     


    img111553942_1.jpg Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Recommends Voting Items 1. The election of the three nominees for director named in the Proxy Statement, to hold office until the 2027 Annual Meeting of Stockholders. For Nominees: 01) Daniel N. Swisher Jr. 02) Frank Witney, Ph.D 03) Eric Bjerkholt 2. The approval of an amendment and restatement of the Company’s Amended and Restated 2008 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 5 million shares and to make certain other changes thereto as described further in the accompanying Proxy Statement. For 3. The approval of an amendment and restatement of the Company’s Amended and Restated Employee Stock Purchase Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 2 million shares. For 4. The approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. For 5. The ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. For NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V46689-P09249

     


    Get the next $CERS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CERS

    DatePrice TargetRatingAnalyst
    4/12/2024$5.00Buy
    Craig Hallum
    1/20/2023Buy → Neutral
    BTIG Research
    1/17/2023$3.75Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $CERS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus' INTERCEPT™ Blood System in Routine Clinical Practice

    Cerus Corporation (NASDAQ:CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen and its subsidiary organization, the German Red Cross Blood Donation Service North-East. The prospective, multicenter, non-interventional safety study, sponsored by DRK Blood Donation Service Baden-Württemberg-Hessen, is the first of its kind in Germany to evaluate the routine use of pathogen-inactivated platelet concentrates utilizing the INTERCEPT Blood System in a clinical setting. Platelet concentrates (PC) are an important part of the blood supply in Germany. They are needed for patients with low platelet count or impaired platelet

    1/22/26 7:30:00 AM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook

    Preliminary Full-Year 2025 Product Revenue of $206.1 Million Full-Year 2026 Product Revenue Expected to be $224 Million to $228 Million, Reflecting 9%-11% Growth, Year-Over-Year Cerus Corporation (NASDAQ:CERS) today announced preliminary product revenue for the fourth quarter and full-year 2025, as well as provided 2026 product revenue guidance and select milestones for 2026. "2025 was a remarkable year for Cerus, as patient access to INTERCEPT treated blood components increased meaningfully around the world," said William "Obi" Greenman, Cerus' president and chief executive officer. "During 2025, based on the number of kits sold, we helped our blood center customers produce approxima

    1/11/26 4:00:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces Group Purchasing Agreement with Blood Centers of America

    Cerus Corporation (NASDAQ:CERS) announced today that it has entered into a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S. BCA member blood centers produce approximately half of the U.S. platelet and cryoprecipitate supply. The agreement covers Cerus' entire INTERCEPT product line. Under this agreement, Cerus will partner with BCA to drive expanded access to pathogen reduction technology for platelets, plasma and pathogen reduced cryoprecipitated fibrinogen complex, commonly referred to as INTERCEPT Fibrinogen Complex, or IFC, across their blood center membership. "We are excited to partner with BCA and the 60+ independent co

    12/10/25 4:15:00 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Jensen Chrystal sold $93,500 worth of shares (55,000 units at $1.70), decreasing direct ownership by 7% to 728,294 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    11/26/25 4:07:46 PM ET
    $CERS
    EDP Services
    Technology

    Director Gregory Dean A. bought $31,250 worth of shares (25,000 units at $1.25), increasing direct ownership by 41% to 86,725 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    8/25/25 3:25:00 PM ET
    $CERS
    EDP Services
    Technology

    Director Witney Frank was granted 60,000 shares, increasing direct ownership by 27% to 280,059 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    6/4/25 6:53:35 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gregory Dean A. bought $31,250 worth of shares (25,000 units at $1.25), increasing direct ownership by 41% to 86,725 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    8/25/25 3:25:00 PM ET
    $CERS
    EDP Services
    Technology

    Director Gregory Dean A. bought $2,932 worth of shares (1,725 units at $1.70), increasing direct ownership by 3% to 61,725 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    1/2/25 5:46:11 PM ET
    $CERS
    EDP Services
    Technology

    Shan Hua bought $4,975 worth of shares (2,500 units at $1.99), increasing direct ownership by 8% to 32,386 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    5/14/24 6:30:46 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Cerus with a new price target

    Craig Hallum initiated coverage of Cerus with a rating of Buy and set a new price target of $5.00

    4/12/24 8:00:30 AM ET
    $CERS
    EDP Services
    Technology

    Cerus downgraded by BTIG Research

    BTIG Research downgraded Cerus from Buy to Neutral

    1/20/23 10:02:56 AM ET
    $CERS
    EDP Services
    Technology

    Cerus downgraded by Stephens with a new price target

    Stephens downgraded Cerus from Overweight to Equal-Weight and set a new price target of $3.75

    1/17/23 7:57:35 AM ET
    $CERS
    EDP Services
    Technology

    $CERS
    SEC Filings

    View All

    Cerus Corporation filed SEC Form 8-K: Leadership Update

    8-K - CERUS CORP (0001020214) (Filer)

    1/23/26 4:24:31 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CERUS CORP (0001020214) (Filer)

    1/12/26 8:06:36 AM ET
    $CERS
    EDP Services
    Technology

    SEC Form 144 filed by Cerus Corporation

    144 - CERUS CORP (0001020214) (Subject)

    11/24/25 5:17:57 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Leadership Updates

    Live Leadership Updates

    View All

    Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors

    Cerus Corporation (NASDAQ:CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year. "We are very pleased to welcome Mr. Gregory to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, h

    7/2/24 4:00:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer

    Cerus Corporation (NASDAQ:CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. "We are excited to welcome Alicia to the Cerus team," said William "Obi" Greenman, Cerus' president and chief executive officer. "As we advance on key global commercial and pipeline initiatives, our talent, leadership and organization structure across all levels of the organization w

    9/27/23 8:30:00 AM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors

    Cerus Corporation (NASDAQ:CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors. "We are pleased to welcome Dr. Shan to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Dr. Shan is an accomplished, leading voice in the transfusion community, with more than twenty-five years of experience in the field, bringing a wealth of knowledge and insight to our Board. In addition, Dr. Shan has extensive experience with international blood bank practices including the Chinese transfusion market. We expect to benefit from Dr. Shan's expertise as we co

    7/5/22 5:00:00 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cerus Corporation

    SC 13G/A - CERUS CORP (0001020214) (Subject)

    11/12/24 9:53:11 AM ET
    $CERS
    EDP Services
    Technology

    SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

    SC 13G/A - CERUS CORP (0001020214) (Subject)

    2/14/24 4:21:51 PM ET
    $CERS
    EDP Services
    Technology

    SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

    SC 13G/A - CERUS CORP (0001020214) (Subject)

    2/13/24 5:01:03 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Financials

    Live finance-specific insights

    View All

    Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance

    Third Quarter Total Revenue up 19% to $60.2 Million; Record Product Revenue of $52.7 Million, Up 15% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $202 Million - $204 Million Cerus Corporation (NASDAQ:CERS) announced today financial results for the third quarter ended September 30, 2025, and provided a business update. "We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by our INTERCEPT Blood System. Fu

    11/6/25 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025

    Cerus Corporation (NASDAQ:CERS) announced today that its third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will be av

    10/16/25 4:00:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces Second Quarter 2025 Financial Results

    Second Quarter Total Revenue of $60.1 Million; Record Product Revenue of $52.4 Million, Up 16% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $200 Million - $203 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. "With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter's commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio. The early launch and adoption of our next gen

    8/5/25 4:01:00 PM ET
    $CERS
    EDP Services
    Technology